A Review of Bone-Targeted Therapies

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

Mark Garzotto, MD, discusses data with aglatimagene besadenovec plus valacyclovir and EBRT in intermediate- to high-risk localized prostate cancer.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.

The addition of olaparib to radium‐223 did not significantly impact PROs compared with radium‐223 alone in mCRPC with bone metastases.